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Chronic obstructive pulmonary disease (COPD) is a common preventable and treat-
able disease characterized by persistent airflow limitation, which is usually progressive
and associated with an enhanced chronic inflammatory response to noxious particles or
gases in the airways and the lung. COPD is a leading cause of morbidity and mortality
worldwide and is more prevalent in smokers, in those over 60 years of age and in men
more than in women (1).
Cigarette smoking is the best-studied COPD risk factor (2), but not all people with
the same smoking history will develop COPD, due to differences in genetic predisposi-
tion to the disease. The best documented genetic risk factor is deficiency of alpha-1-
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The aim of this study was to test the hypothesis that glu-
tathione-S-transferase (GST) genotypes were associated
with COPD. GSTP1, GSTM1 and GSTT1 genotypes were
determined by DNA methods and GST activity spectro-
photometrically in older male Caucasian Croats (non-
-smokers, ex-smokers, and smokers) with stable COPD
(n = 30) and sex/age matched controls (n = 60). The dis-
tribution of GSTP1 genotypes and alleles in controls vs.
COPD showed a statistical difference (p < 0.05). The odds
ratio of CC/CT+TT (wild type GSTP1 exon 6 vs. joint he-
terozygous and mutant homozygous GSTP1 exon 6) was
10.000 and statistically different (p = 0.002). In this study,
the GSTP1 mutant genotype of exon 5 (GG), as well as
GSTP1 mutant and heterozygous genotypes of exon 6 (TT
and CT), were suggested to be genetic contributors to
COPD susceptibility. Null GSTM1, null GSTT1 and joint
GSTM1/GSTT1 null genotypes were not disease associ-
ated. Serum GST was not associated with GST genotypes
and COPD or smoking history in our study subjects. Con-
clusions drawn from the study should be further support-
ed and clarified by studies with larger sample sizes.
Keywords: glutathione S-transferases (GST), polymorphism,
COPD, alpha-1-antitrypsin, lactate dehydrogenase
* Correspondence; e-mail: izuntar@pharma.hr
-antitrypsine (AAT) (1). Nowdays, there is increasing evidence that the development of
COPD may be associated with the genetic variation in the xenobiotic-metabolizing en-
zymes such as microsomal epoxide hydrolase (mEPHX), glutathione S-transferases (GSTs),
heme oxygenase-1 (HO-1), catalase (CAT), superoxide dismutase (SOD) and cytochrome
P450 (CYP) (3).
GSTs are a large family of enzymes participating in detoxification of endogenous
and environmental xenobiotics (4).
GSTM1 is involved in the metabolism of diol epoxides stemming from polycyclic
aromatic hydrocarbons (PAHs) and ROS (5). GSTT1 can detoxify methylating agents, pesti-
cides and many chemicals present in cigarette smoke (6). Null genotypes of GSM1 and
GSTT1 result in a complete lack of the corresponding enzyme activities. GSTP1 shares
some substrate specificity with GSTM1, being active towards many PAH epoxides, in-
cluding benzo(a)pyrene (5). Several polymorphisms have been detected in the GSTP1 gene,
including C341T (Ala114Val) substitution in exon 6 and A313G (Ile105Val) substitution
in exon 5, resulting in an altered enzyme activity (7).
Many studies have reported on the association between GST gene polymorphisms
and pulmonary disorders but with controversial results (8–14). Also, marked intra- and
inter-ethnic differences in frequencies of common GST mutations have been revealed by
many studies (5, 7, 9, 12, 13, 15, 16). However, the association of GST genotypes and GST
enzyme activity in COPD (17) is not thoroughly investigated yet.
The aim of our study was to determine GSTP1, GSTM1 and GSTT1 polymorphism
distribution in a group of elderly men diagnosed with stable COPD and sex/age match-
ed controls and to investigate the association between GST genotypes and COPD. Also,
serum GST activity was investigated in connection with GST genotypes and smoking
history.
EXPERIMENTAL
Subjects
A total of 90 subjects were included in the study. The first group, serving as the con-
trol, comprised a total of 60 healthy male subjects (mean age 63 ± 5), out of which 19
were non-smokers (31 %), 16 (27 %) ex-smokers who stopped smoking before 1–32 years
before, and 25 current life-long smokers (42 %, pack per year = 36.2 ± 9.4). Upon approval
issued by Ethics Committee of the University Hospital for Lung Diseases (Zagreb, Croa-
tia), all subjects signed an informed consent prepared in line with the Helsinki Declara-
tion, and filled out a structured questionnaire answering questions about their smoking
habits, blood pressure and possible co-morbidities. Individuals suffering from renal, car-
diac, gastrointestinal, endocrine and liver diseases, as well as those suffering from hy-
pertension and asthma, were excluded from the study, and so were the subjects on any
drug and/or vitamin/mineral therapy and alcoholics (consuming > 50 g of alcohol per
day). The same holds for the subjects taking calcium antagonists, diuretics, laxatives and
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antibiotics. Inclusion merits were based on standard blood and urine biochemistry, as
well as on spirometry results which was unanimously required to be normal.
The second group included 30 male COPD patients (mean age 65 ± 7) treated at the
Jordanovac University Hospital for Pulmonary Diseases, adjudicated to be stable for at
least 3 months and needing no hospitalization and/or therapy modification. Their medi-
cation therapy, lasting 1–7 years, consisted of a combination of long-acting (salbutamol,
100–1000 µg) and short-acting (salmeterol, 2 ´ 50 µg) beta2-agonists as required, as well
as administration of an anticholinergic or parasympatholytic (ipatropium bromide,
40–200 µg) agent and one of the xantine preparations (Teolin 300 mg, 2 ´ 1, or Teotard,
200–350 mg bid). All COPD subjects were without oral corticosteroids. The COPD group
included patients (smokers and ex-smokers, pack per year = 42 ± 15, only four non-
-smokers) having FEV1 of 46.6 ± 12.1 %, FEV1/FVC < 0.7, classified as COPD grade II
(moderate) or III (severe) according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) standards (1). Twelve patients (40 %) were former smokers who
stopped smoking before 5–46 years, 14 (46 %) were current life-long smokers, while 4 (14 %)
had never smoked at all. COPD patients with coexisting renal, hepatic, endocrine or gas-
trointestinal diseases, and those taking > 50 g of alcohol daily, were excluded from the
study. No significant difference was found between healthy smokers and COPD smo-
kers in respect to the number of cigarettes consumed per year (pack per year).
In all study subjects recruited in one year, blood samples were collected between
7:00 and 9:00 a.m. after overnight fasting. The serum was separated by means of 2000 x g
10-minute centrifugation, and stored at –20 °C until analysis. Spirometry was performed
on the same day.
Biochemical analysis of GST and LDH activity and AAT concentration
Genomic DNA was extracted from whole blood samples using a modified salting-
-out procedure (19). Glutathione S-transferase (GST) and lactate dehydrogenase (LDH)
activity, along with alpha-1-antitrypsin (AAT) concentration, were determined in serum
samples of all subjects. LDH activity was measured using the standard method and avail-
able tests (Olympus Diagnostica GmbH, Ireland) intended for Olympus AU 400 auto-an-
alyzer. AAT concentration was determined by means of the radial immune-diffusion
(RID) technique using commercially available standard and mono-specific anti-sera (Berin-
werke AG, Germany). Serum GST activity was determined using the spectrophotometric
method described by Habdous et al. (20), on a Trace spectrophotometer (Trace Scientific
Ltd, Australia) utilising 1-chloro-2,4-dinitrobenzene (CDNB, Sigma) as a substrate.
Determination of GSTP1, GSTM1 and GSTT1 genetic polymorphisms
A313G and C341T GSTP1 gene polymorphisms were determined using the polyme-
rase chain reaction-restriction fragment length polymorphism (PCR-RFLP), as previous-
ly described in detail (21, 22). To detect deletions in GSTM1 and GSTT1 genes, a multi-
plex PCR was performed including b-globin gene amplification employed as a DNA
sample control, as previously reported (15).
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Statistical analysis
The frequency of each GST genotype and association between cases and controls
were assessed by the c2-test. Odds ratios (OR) and 95 % confidence interval (CI) were
used to describe the strength of association.
The influence of smoking histories (smokers, non-smokers and ex-smokers) on the
AAT concentration and activity of GST and LDH in healthy individuals and COPD pa-
tients were tested with one way ANOVA and one way ANOVA on ranks (Kruskal Wallis
test) for parametric and nonparametric data, respectively. Also, post hoc multiple com-
parisons were performed using the Holm-Sidak test (one way ANOVA) and Dunn’s test
(one way ANOVA on ranks).
The influence of GST genotypes (GSTP1, GSTM1 and GSTT1) on the serum GST ac-
tivity in groups (COPD and healthy subjects) and in different genotype and smoking
history groups were analyzed by two way ANOVA with post hoc comparisons (Holm-
-Sidak test).
The SigmaStat statistical program (version 3.5, SPSS Inc., Chicago, Illinois, USA) was
used for all analyses except for odds ratio calculation by the MedCalc statistical program
(version 7.0.0.2., MedCalc Software, B-9030, Mariakerke, Belgium). The value of p < 0.05
was considered statistically significant.
RESULTS AND DISCUSSION
GST and LDH activity and AAT concentration
GST and LDH activity and AAT concentration levels (median and interquartile range)
in healthy individuals and COPD patients subdivided according to their smoking histo-
ries are presented in Table I.
No statistically significant difference in GST activity between and within multiple
groups was found. Unlike GST activities, the difference in AAT and LDH between and
within groups reached statistical significance (p < 0.05, Table I, abbreviation marks a–d).
It is known that subjects with AAT deficiency have an increased risk of severe air-
flow obstruction and experience an accelerated lung function decline (23). In the present
study, the total AAT value registered in COPD patients was higher than that registered
in the controls and non-smoking controls in particular; both comparisons revealed sta-
tistically significant differences (Table I). Also, the value of COPD ex-smokers was sig-
nificantly higher than the value for total controls as well as subgroups of healthy sub-
jects (Table I). Interestingly, there were no significant differences between healthy smokers
and COPD-smokers, and healthy non-smokers and COPD ex-smokers. Since AAT is
known to be an acute phase protein, these results confirmed the existence of inflamma-
tion in stable COPD patients, but also implicated the complex mechanism in COPD de-
velopment.
The significantly elevated LDH activity (Table I) seen in COPD was probably associ-
ated with chronic hypoxia and thus a higher supply of lactate posing as this enzyme’s
substrate, as suggested earlier (24). In other words, this rise in LDH activity might be at-
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tributed to the facilitated lactate oxidation to pyruvate, which could be subsequently
used in the tricarbon acid cycle for energy production. But, LDH showed a statistically
significant difference within the group of COPD patients. Non-smokers revealed higher
activity than smokers and ex-smokers, indicating that other factors, as well as inflamma-
tion and a complex mechanism are involved in increased LDH value of COPD subjects,
regardless of the best-studied COPD risk factor smoking history.
GSTP1, GSTM1 and GSTT1 genetic polymorphisms
The results of genotype determination, along with those of allele frequency, are giv-
en in Table II.
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Table I. Glutathione S-transferase and lactate dehydrogenase activity, and alpha-1 antitrypsine
concentration in healthy individuals and in COPD patients
GST (U L–1) AAT (g L–1) LDH (U L–1)
Median (interquartile range)
Healthy
subjects
Total
(n = 60)
69.00
(54.00–80.25)
1.54a,b
(1.34–2.11)
170.00d
(154.50–191.00)
Smokers
(n = 25)
69.00
(54.75–81.25)
1.82
(1.33–2.44)
160.00d
(147.50–197.75)
Non-smokers
(n = 19)
67.00
(52.75–79.00)
1.46a,b
(1.28–1.88)
170.00d
(154.50–199.00)
Ex-smokers
(n = 16)
72.00
(63.00–76.00)
1.50b
(1.42–1.87)
176.00d
(171.25–178.48)
COPD
Total
(n = 30)
66.00
(53.00–76.00)
1.94a
(1.55–2.39)
181.00d
(159.75–216.50)
Smokers
(n = 14)
60.00
(48.50–73.00)
1.88
(1.48–2.43)
175.00c
(142.00–191.00)
Non-smokers
(n = 4)
62.50
(54.00–71.50)
1.79
(1.62–3.00)
390.00c,d
(233.25–531.75)
Ex-smokers
(n = 12)
70.00
(58.50–90.75)
1.98b
(1.59–2.40)
198.50c,d
(162.00–216.00)
GST – glutathione S – transferase, LDH – and lactate dehydrogenase activity, AAT – alpha-1 antitrypsine,
COPD – chronic obstructive pulmonary disease
a Significant difference between the groups (total COPD vs. control non-smokers, total COPD vs. total healthy
subjects), p < 0.05.
b Significant difference between the groups (COPD ex-smokers vs. healthy total, COPD ex-smokers vs. healthy
non-smokers, COPD ex-smokers vs. healthy ex-smokers), p < 0.05.
c Significant difference between the groups (COPD non-smokers vs. COPD smokers, COPD non-smokers vs.
COPD ex-smokers), p < 0.05.
d Significant difference between the groups (COPD total vs. healthy total, COPD total vs. healthy smokers,
COPD total vs. healthy non-smokers, COPD non-smokers vs. healthy total, COPD non-smokers vs. healthy
smokers, COPD non-smokers vs. healthy ex-smokers, COPD non-smokers vs. healthy non-smokers), p < 0.05.
The comparison of actual GSTP1 genotype distributions and those predicted by the
c2-test based on allele frequencies, showed the population covered by this study to be in
Hardy-Weinberg equilibrium (HWE), indicating that the control and the COPD group
122
I. @untar et al.: GSTP1, GSTM1 and GSTT1 genetic polymorphisms and total serum GST concentration in stable male COPD, Acta
Pharm. 64 (2014) 117–129.
Table II. Genotypic frequencies of GSTP1, GSTM1 and GSTT1 polymorphisms in older male Croats
Genotype
COPD
(n = 30)
Healthy sub-
jects (n = 60)
p-valuea
OR
(95 % CI)
GSTP1, exon 5, n (%)
AA 10 (33) 34 (57)
AG 16 (54) 25 (41)
GG 4 (13) 1 (22) 0.021 9.077 (0.967–85.211)b
AG+GG 20 (67) 26 (43) 0.062 2.615 (1.048–6.529)c
A/G allele freq. 60/40 78/22 0.009
HWE 0.864 0.480
GSTP1, exon 6, n (%)
CC 2 (3) 25 (42)
CT 21 (73) 25 (42)
TT 7 (24) 10 (16) 0.003 1.522 (0.514–4.503)b
CT+TT 28 (93) 35 (58) 0.002 10.000 (2.179–45.882)c
C/T allele freq. 40/60 63/37 0.002
HWE 0.167 0.814
GSTM1, n (%)
Present 16 (53) 33 (55)
Null 14 (47) 27 (45) 0.940 1.069 (0.444–2.577)
GSTT1, n (%)
Present 23 (77) 47 (78)
Null 7 (23) 13 (22) 0.929 1.100 (0.387–3.130)
Combined GSTM1 and GSTT1
Present/present 14 (46) 31 (52) 1.006 (0.294–3.448)d
Null/present 9 (30) 16 (27)
Present/null 2 (7) 2 (3)
Null/null 5 (17) 11 (18) 0.816 1.222 (0.508–2.939)e
COPD – chronic obstructive pulmonary disease, OR – odds ratio, HWE – Hardy-Weinberg equilibrium
a p-value of c2-test
b GG vs. AA+AG and TT vs. CC+CT.
c GG+AG vs. AA and TT+CT vs. CC.
d Null/null vs. present/present
e Null/null+heterozygous (null/present and present/null) vs. present/present
were sufficiently random and representative. The differences in GSTP1 exon 5, GSTP1
exon 6 and allele frequencies (A/G and C/T) found in the control and COPD groups
were statistically significant (p = 0.021, p = 0.003, p = 0.009 and p = 0.002, respectively).
When compared to the wild AA genotype, the calculated relative risk for combined cate-
gory of mutant GG and heterozygous AG genotypes did not reach statistical significan-
ce. Compared to the CC genotype, the odds ratio for the combined category of CT and
TT genotypes was 10.000 (95 % CI 2.179–45.882) and reached statistical significance (p =
0.002).
These results suggested that the mutant GSTP1 exon 5 genotype (GG) as well as
mutant (TT) and joint genotypes of GSTP1 exon 6, mutant and heterozygous (TT+CT),
could be genetic contributors to COPD susceptibility, while homozygous wild types (AA
and CC) were not. Similarly, Lakhdar et al. (25) found the Tunisians carrying a GSTP1
Val105 allele were at higher COPD risk. In addition, the meta-analysis completed by Yan
et al. (26) suggested that the GSTP1 105Val/Val genotype was an important genetic con-
tributor to COPD susceptibility. In contrast, Yim et al. (13) showed no association be-
tween exon 5 and COPD in Koreans, while Ishii et al. (12) showed an increased preva-
lence of homozygous GSTP1 exon 5 wild type in Japanese COPD patients. Smolonska et
al. (27, 28) reported that GSTP1 105Val polymorphism had no COPD protective role in
Asian population.
In the COPD group, the portion of null GSTM1 genotype carriers amounted to 47 %
compared to 45 % in the controls. As regards the GSTT1 genotype, the percent share of
null GSTT1 COPD-diagnosed carriers was 23 % compared to 22 % in the controls. The
distribution of GSTM1 and GSTT1 genotypes in the COPD vs. controls was not signifi-
cantly different. Calculated odds ratios for both genotypes were as follows: 1.069 for null
GSTM1 and 1.100 for null GSTT1. The distribution of combined null GSTM1/GSTT1 ge-
notypes and combined heterozygous (null/present and present/null) GSTM1/GSTT1
genotypes compared to combined both present GSTM1/GSTT1 genotypes was not sig-
nificantly different.
A cohort study performed in Swiss general population showed a large proportion of
Caucasians to carry one or both GST gene deletions (around 20 % of GSTT1 gene dele-
tion, around 50 % GSTM1 gene deletion and around 10 % of GSTT1/GSTM1 gene dele-
tion carriers) (29). Similar results relative to null GSTT1, null GSTM1, and joint GSTM1/
GSTT1 null genotypes, were obtained in our study (Table II) as well. In the Korean (13)
and Slovak populations (30), no association between GSTM1 and GSTT1 genetic poly-
morphism and COPD was found. In agreement with these findings, our results showed
no association between GSTM1 and GSTT1 gene polymorphisms and COPD either. The
paper by Mehrotra et al. (31) suggested that GSTT1, but not GSTM1 null genotype, might
be associated with COPD susceptibility. A strong correlation between the EPHX1 113
mutant homozygote with lower bronchodilator responses in smoking-related COPD was
found by Chen et al. (32).
Some research articles have shown the analysis of gene combination to be important
for the estimation of gene-COPD relation. The study of Slovak population suggested the
combination of the homozygous exon 3 mutant variant of EPHX1 gene and GSTM1 null
genotype to be a significant predictor of increased COPD susceptibility, although none
of the tested gene polymorphisms alone were associated with an increased COPD risk,
at least not to a statistically significant extent (30).
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He et al. (11) showed the combination of GSTT1 null genotype and GSTM1 and GSTP1
risk genotypes to be related to lung function impairments, while Lakhdar et al. (33) con-
cluded that combined GSTM1, GSTT1, GSTP1 and EPHX1 genetic polymorphisms may
have favourable effects on redox balance in COPD patients. Rodriguez et al. (14) found
the modulating role of GSTP1 in COPD to take effect only in smokers lacking AAT. The
study of Cheng et al. (9) proposed the combination of genetic variants including at least
one mutant EPHX exon 3 allele, GSTM1 null and homozygous Ile105 GSTP1 genotypes
to be a significant indicator of COPD susceptibility in Taiwanese population.
The association between GST genotypes, total serum GST activity and smoking history
Association between serum GST and different GST genotypes in COPD and healthy
subjects were tested by two way ANOVA and presented in Figs. 1a–d.
Also, based on their genotypes, the tested subjects were divided into two groups: (i)
combined wild GST genotype consisting of GSTP1 exon 5 wild type/GSTP1 exon 6 wild
type/GSTM1 present/GSTT1, and (ii) non-wild combined GST genotype consisting of
all other genotypes, and compared for their total GST serum values. No combination of
wild GST genotypes was found among COPD patients. Accordingly, no influence of
combined wild GST genotypes (all wild type GST genotypes) as well as non-wild com-
bined GST genotype on GST activity among different smoking history groups of COPD
patients and controls was recorded, as seen in Fig. 1.
Wild type GST genetic combination was seen in more than 5 control subjects (2 smo-
kers, 2 non-smokers, and 1 ex-smoker). Their GST activity was 85.50 ± 16.29 U L–1 (me-
dian, 83 U L–1; range, 69–107 U L–1). In the remaining control subjects (n = 55; 23 smo-
kers, 17 non-smokers, and 15 ex-smokers), a combination of GST genotypes was found,
their GST activity being 66.16 ± 15.79 U L–1 (median, 67 U L–1; range, 38–111 U L–1).
Comparison of these two control subgroups yielded a statistically significant difference
(p = 0.023, t-test), but this observation has no power and should be further clarified in a
study involving a larger sample size. When comparing the non-wild GST genotype-car-
rying control and non-wild GST genotype-carrying COPD group members, no statisti-
cally significant difference was found by the t-test, nor in the comparison of the wild
GST genotype-carrying control and the non-wild GST genotype-carrying COPD group.
The total GST activity seen in the controls and COPD group, as well as in smoking
history-based (Table I) and GST genotype-based subgroups (Fig. 1), was not significantly
different. In addition, the influence of different GST genotypes on GST activity among
controls and COPD patients with different smoking history (smokers, ex-smokers and
non-smokers) was not found in this study (Fig. 1). This is not surprising, since many
GST genes regulate the enzyme production and,a single abnormality,may not be ade-
quate to reduce the level of GST activity (34).
The Chinese study, which involved a similar number of controls but more COPD
patients, showed that plasma GST activity was significantly higher in patients compared
to controls, irrespective of their different genotypes (17). Also, that study concluded that
polymorphisms of GSTT1, GSTM1 and GSTP1 genes were unlikely to be involved in the
pathogenesis of COPD.
To the best of our knowledge, only one study reported GST activity measurements
in the plasma of COPD patients together with determination of different GST genotypes
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in smokers with or without COPD (17); thus the relative importance of GST in human
lungs still remains unknown. In our study, serum GST activity seen in COPD patients
was lower compared to the coresponding healthy controls, but the differences were not
statistically significant (Table I). This trend of GST activity in the sera of patients with
stable COPD could be probably explained by the drop of the GSH level in COPD and in-
creased oxidative stress occuring in the lungs and systemically in COPD (1).
Recently, Bentley et al. (35) investigated the association of the variants of genes en-
coding antioxidant enzymes with the lung function phenotypes. They confirmed that
single nucleotide polymorphisms (SNPs) in genes associated with glutathione synthesis
and encoding glutathione S-transferases were associated with the lung function pheno-
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Fig. 1. Serum GST activity according to GSTP1: a) exon 5, b) exon 6, c) combined GSTM1 and GSTT1
and d) combined GSTP1 exon 5 and exon 6 genotypes in COPD patients and healthy subjects.
Association between serum GST and different GST genotypes in COPD and healty subjects was
performed by two way ANOVA. Statistical difference was not found (p > 0.05). wt – wild type geno-
type; mt – mutated homozygous genotype; ht – heterozygous genotype; comb – combined genotypes;
HNS – healthy non-smokers; HS – healthy smokers; HES – healthy ex-smokers; COPD-NS – COPD
non-smokers; COPD-S – COPD smokers; COPD-ES – COPD ex-smokers.
type. Also, their results supported a key role for the mitochondria and mitochondrial an-
tioxidant enzymes in the lung and systemic response to ROS in cigarette smoke expo-
sure.
Our results showed the presence of a systemic oxidant/antioxidant imbalance typi-
cal of COPD, with the measured parameters not being affected by smoking, so that we
concluded that this imbalance was probably smoking independent.
One limitation of the present study was that only older male subjects were involv-
ed. However, it is known that COPD is more prevalent in those over the age of 60 and in
men than in women. Another limitation was that this was a case-control study with a
relatively small number of recruited subjects. However, the study groups were homoge-
nous, sex and age matched controls and COPD subjects, with very well defined inclu-
sion and exclusion criteria. Conclusions drawn from the study should be further sup-
ported and clarified by studies with larger sample sizes, including women and not only
stable, but also exacerbating COPD patients.
CONCLUSIONS
Our study suggested that the GSTP1 mutant genotype of exon 5 (GG), and also
GSTP1 mutant and heterozygous genotypes of exon 6 (TT and CT), could be genetic con-
tributors to COPD susceptibility while null GSTM1, null GSTT1, joint GSTM1/GSTT1
null genotypes and wild type GSTP1 genotypes (AA and CC) were not. No influence of
GST genotypes on serum GST activity in COPD subjects and controls subdivided ac-
cording to smoking history was found.
According to our study results, cigarette smoking as one of the possible, but not in-
disputable COPD causal factors had no major and unequivocal impact on the serum
level of GST, AAT and LDH, as there was no statistically significant difference between
healthy subject subgroups divided according to their smoking history (non-smokers, ex-
-smokers and smokers).
In addition, an elevated and significantly higher level of AAT, known as an acute
phase protein, was found in the group of COPD ex-smokers compared to healthy ex-
-smokers. As there were no significant differences between healthy smokers and COPD-
-smokers, and healthy non-smokers and COPD non-smokers, the results imply the com-
plexity of the mechanism, not underlying the observed effects only inflammation and
influence of smoking. Surprisingly, a significantly higher level of LDH was found in
COPD non-smokers in comparison with COPD smokers and ex-smokers, but also in
comparison with healthy control subgroups. These results supported hypoxia and in-
flammation as a part of the disease, but showed a complex causal mechanism and need
for further investigations and clarifications.
Further studies are needed to clarify the role of genes, serum GST activity and smo-
king status in COPD onset; their sole and combined roles should be explored in a larger
population group involving not only stable, but also exacerbating COPD patients.
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